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A 56 year old woman was referred to the rapid access chest pain
clinic with stable angina pectoris. Her only cardiovascular risk
factor was a family history of atherosclerosis, with her mother
suffering from myocardial infarction at 50. Her body mass index
was 20 kg/m2 and the main abnormality on examination was
the eye sign shown in . Fasting serum cholesterol and low
density lipoprotein were both markedly raised at 12.2 mmol/L
and 9.3 mmol/L, respectively. Triglyceride levels were relatively
normal at 1.9 mmol/L. Given the history, examination, and lipid
abnormality, what further blood test would confirm the
underlying diagnosis?
Eye signs in cardiovascular disease: when the patient looks
upward, a symmetrical abnormality is visible in both eyes
Answer
Genetic blood testing for low density lipoprotein receptor
mutation to confirm the diagnosis of heterozygous familial
hypercholesterolaemia.
Discussion
This presentation of premature coronary artery disease in a
relatively young woman with striking corneal arcus and fasting
serum cholesterol of 12.2 mmol/L is strongly suggestive of
underlying heterozygous familial hypercholesterolemia. Genetic
blood testing for low density lipoprotein receptor mutation
would confirm the diagnosis, although the National Institute
for Health and Care Excellence (NICE) recommends that this
step should be performed by a specialist after genetic counselling
and initiation of cascade testing.1 Corneal arcus in this setting
reflects widespread tissue lipid deposition and is correlated with
both calcific atherosclerosis and xanthomatosis in patients with
familial hypercholesterolemia.2 The condition is underdiagnosed,
and while physical signs including corneal arcus and tendon
xanthomas are important clues, they lack sensitivity and
specificity and are thus not required for diagnosis.3 Familial
screening can be helpful for early diagnosis and treatment, thus
reducing the risk of premature cardiovascular events.
Initial management of heterozygous familial
hypercholesterolaemia includes stabilisation with a statin. If
low density lipoprotein is >3.5 mmol/L despite treatment and
the patient has documented cardiovascular disease, then updated
NICE guidelines suggest that fortnightly evolocumab by
subcutaneous injection can be added.4 In the absence of
established cardiovascular disease these patients require greater
elevations of low density lipoprotein (>5 mmol/L) to qualify
for treatment with evolocumab or other proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors.
In the recent FOURIER trial,5 27 564 patients at risk of
cardiovascular disease who were already on an optimal statin
regime were randomised to placebo or evolocumab. Over a
median follow-up of 2.2 years, the primary end point (composite
of cardiovascular death, myocardial infarction, stroke,
hospitalisation for unstable angina, or coronary
revascularisation) was reduced in patients randomised to
evolocumab compared with placebo (9.8% v 11.3%; hazard
ratio 0.85; 95% confidence interval 0.79 to 0.92; P<0.001).
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The patient looking upwards reveals a dense and striking
white circumferential ring around the cornea (corneal arcus)
reflecting cholesterol rich lipid deposits in the context of
familial hypercholesterolaemia
Patient outcome
Molecular genetic testing showed a heterozygous defect in the
low density lipoprotein receptor, confirming heterozygous
familial hypercholesterolaemia. Despite stabilisation with
atorvastatin 80 mg, the low density lipoprotein concentration
remained >5 mmol/L. The patient was started on evolocumab.
The patient subsequently stabilised on evolocumab and
atorvastatin. The most recent total cholesterol showed a
reduction of 55% to 5.5 mmol/L and a reduction of low density
lipoprotein of 75% to 2.3 mmol/L.
Invasive coronary angiography revealed diffuse but
non-obstructive triple vessel coronary artery disease. She was
randomised in the CorMicA trial (Coronary MICrovascular
Angina, clinicaltrials.gov NCT03193294) with invasive metrics
of coronary artery function, confirming a reduced coronary flow
reserve and microvascular angina as the cause of her symptoms.
Angina was much improved after targeted titration of medical
treatment.
Learning points
Physicians should consider familial hypercholesterolaemia
in patients with strikingly elevated cholesterol.
Physical signs including corneal arcus and tendon xanthomas
are important clues, however these are not required for
diagnosis (this might require genetic testing).
Patients with familial hypercholesterolaemia are at very high
risk of cardiovascular complications. This is modifiable with
aggressive secondary prevention including statins and
possibly PCSK9 inhibitors.
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